It's worth nothing. Pure manipulation. They could take private the whole company for a lot less. They are just trying to pump the share price. Should end the day below a 10% gain. Went short in pre-market.
When adjusting for non-recurring gains my calculation arrives at roughly $0.08 per share for the combined company. A roughly 10% yield pretty much in line with most of its peers.
Not really. I shorted the shares into this morning's uptick. Numbers were mixed at best and the dividend announcement was expected. A roughly 10% yield is quite common for tanker stocks so I don't see much upside for the shares from here. Actually I think there will be some pressure on the share price starting next week once the former Frontline 2012 shareholders will be able to sell their new Frontline shares into the market.
Yes and no. Adjusted eps for FRO was just $0.045 but you need to take the earnings of Frontline2012 into account. Unfortunately the company's earnings haven't been adjusted for one time items but based on my calculations the company will declare a dividend of $0.08 in December.
Vivint wasn't bought for its installations business but for its project pipeline. Vivint numbers were ugly last week and I bet SUNE would love to get out of the deal.
There will be no offer for current shareholders. The company will go to Orbimed in chapter 11. That's it.
What contract are you talking of ? The company just changed its CFO for the third time in two years shortly before an important earnings release, Don't tell me you expect good news.
Fully agree. Bought a sizeable position yesterday. The shares have recovered quickly twice already from much bigger issues relating to the 2014 reserve.
because Tesla expectations were quite low going into the release while expectations for PLUG were sky high - Tesla's shares actually didn't skyrocket by 65% during the last month either.
The fact is that the company's product gross margins were down 35% quarter over quarter which of course is a giant disappointment.
by selling their products at an overall loss of course. Product gross margins down 35% qoq.
Product gross margins are down 35% quarter over quarter despite revenues increasing by 30% qoq. So something seemingly went very wrong here...
Really ? What about the $500 mln bond maturing at the end of 2017 ? What about the $500 mln revolving credit facility up for renewal in 2018 ?
It looks quite clear that the banks will be willing to wait until there's more visibility into any potential recovery after 2017 but they won't wait forever. If the market remains bleak in 2017 the company won't be able to address its refinancing needs then.
Even worse the $500 mln 2014 credit facility was actually terminated in exchange for the covenant relief so available liquidity going forward will remain tight.
With regard to the Zonda: The case will go to arbitration and I am not that sure about the outcome as the company was already compensated for the delay. Clearly they won't get back their prepayments anytime soon.
So today's news isn't actually all that great as it hardly comes as a surprise that the banks are willing to wait for better visibility from 2017 onwards. And seemingly they were well compensated for their concessions.
Should the market not improve materially going into 2017 (which nobody expects) the company will have to restructure their debts as they won't be able to refinance their upcoming debt maturities then
What are you guys dreaming of ? The company already announced they will run out of cash before quarter end so hopefully for the remaining employees Morgan Stanley will put together a deal with Orbimed until then. Shareholders will get nothing of course regardless of the company's agreements with big drugmakers.
Think again. The news says nothing and the company urgently needs cash to make it through the quarter. The news is designed to make use of the at-the-market facility and sell more stock to guys like you.
Also look at the CEO's financial problems disclosed today - he does need a little upside in his shares even more urgently seemingly.
Here's the most important quote from the press release:
"This new Supply Agreement provides minimum purchase commitments from MedImmune for the initial four years following the commercial launch of this biologic, and also has unit pricing for the devices."
Well, we still don't know when this biologic will launch if ever. But Unilife will run out of money long before they will ship anything material to Medimmune.
The shares will end up worthless within 8 weeks.